Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?
Burakoff
Robert
R
Division of Gastroenterology, Center for Digestive Health, Brigham and Women's Hospital, Massachusetts, USA.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000145:classification / Q000188:drug therapy*; D003424:Crohn Disease / Q000145:classification / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D015122:Mercaptopurine / Q000627:therapeutic use; D019804:Mesalamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D012074:Remission Induction; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D019804:Mesalamine; D016572:Cyclosporine; D000069285:Infliximab; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate